


## TL-895

Cat. No.:	HY-139481		
CAS No.:	1415823-49-2		
Molecular Formula:	C <sub>25</sub> H <sub>26</sub> FN <sub>5</sub> O <sub>2</sub>		
Molecular Weight:	447.5		
Target:	Btk		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (558.66 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.2346 mL	11.1732 mL	22.3464 mL
		5 mM	0.4469 mL	2.2346 mL	4.4693 mL
10 mM		0.2235 mL	1.1173 mL	2.2346 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.65 mM); Clear solution				

## BIOLOGICAL ACTIVITY

Description	TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC <sub>50</sub> and a K <sub>i</sub> of 1.5 nM and 11.9 nM, respectively <sup>[1]</sup> . TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research <sup>[2][3][4]</sup> .
IC <sub>50</sub> & Target	IC <sub>50</sub> : 1.5 nM; K <sub>i</sub> : 11.9 nM (BTK) <sup>[1]</sup>

---

## REFERENCES

- [1]. Valeria Di Battista, et al. Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int J Mol Sci
- [2]. A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
- [3]. Study of TL-895 in Subjects With Myelofibrosis
- [4]. Richard D Caldwell, et al. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Sep 12;62(17):7643-7655.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA